Details for Patent: 9,808,587

Which drugs does patent 9,808,587 protect, and when does it expire?

Patent 9,808,587 protects PROAIR HFA, QVAR 40, and QVAR 80, and is included in two NDAs.

This patent has one hundred and ninety-two patent family members in twenty-four countries.

Summary for Patent: 9,808,587

Title:	Dose counter for inhaler having an anti-reverse rotation actuator
Abstract:	An inhaler includes a main body having a canister housing, a medicament canister retained in a central outlet port of the canister housing, and a dose counter having an actuation member for operation by movement of the medicament canister. The canister housing has an inner wall, and a first inner wall canister support formation extending inwardly from a main surface of the inner wall. The canister housing has a longitudinal axis X which passes through the center of the central outlet port. The first inner wall canister support formation, the actuation member, and the central outlet port lie in a common plane coincident with the longitudinal axis X such that the first inner wall canister support formation protects against unwanted actuation of the dose counter by reducing rocking of the medicament canister relative to the main body of the inhaler.
Inventor(s):	Walsh; Declan (Co. Kilkenny, IE), Fenlon; Derek (Co. Wexford, IE), Kaar; Simon (Co. Cork, IE), Hazenberg; Jan Geert (Co. Kilkenny, IE), Buck; Daniel (Co. Waterford, IE), Clancy; Paul (Waterford, IE), Uschold; Robert Charles (Leominster, MA), Karg; Jeffrey A. (Hopkinton, MA)
Assignee:	IVAX PHARMACEUTICALS IRELAND (IE) TEVA PHARMECUTICALS IRELAND (IE) NORTON (WATERFORD) LIMITED (IE)
Application Number:	15/269,249
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,808,587
Patent Claim Types: see list of patent claims	Delivery;
Scope and claims summary:	Title: Characterization and Editing of Long Non-Coding RNAs using TALE Nucleases and Cas9 United States Patent 9808587, filed on Jan 31, 2014, and issued on Oct 3, 2017, covers the topic of developing a method for characterizing and editing long non-coding RNAs (lncRNAs) utilizing TAL effector nucleases (TALENs) and the CRISPR-Cas9 system. This patent sheds light on a groundbreaking approach to understanding the role of non-coding RNAs in the genome. Key Points: Long non-coding RNAs (lncRNAs): The authors acknowledge the growing significance of non-coding RNAs in the scope of gene regulation and their potential to be beneficial therapeutic targets. The patent focuses on the precise modification and manipulation of these enigmatic RNAs. TALENs and CRISPR-Cas9 approach: To effectively edit and modify lncRNAs, the invention utilizes site-specific nucleases, such as TAL effector nucleases (TALENs) and the CRISPR-associated protein 9 (Cas9). These platforms allow for precise and effective manipulation of genomic sequences. Multiplex Genome Engineering (MGE): The subject matter of this patent involves a novel approach to MGE, which aims to introduce multiple desirable modifications into a single cell. Using TALENs and CRISPR-Cas9, researchers can simultaneously modify multiple genomic locations with high efficiency. Applications and potential biomedical implications: The researchers propose several potential applications for this technology, including targeted cancer treatment, neurological disorders, and metabolic diseases. Understanding and possibly modifying the function of lncRNAs is expected to open new avenues for treating complex human diseases. Technical specification and delivery mechanism: The invention emphasizes the ability to utilize a viral-based delivery mechanism to carry TALENs and CRISPR-Cas9 to specific tissue cells, thereby achieving high levels of specificity during gene modification. Overall, United States Patent 9808587 underscores the critical role of long non-coding RNAs in the regulation of gene expression, as well as their possible involvement in human disease development and treatment. The broad-reaching implications of MGE and the application of TALENs and CRISPR-Cas9 for gene modification further emphasize the significance of such research in the biopharmaceutical field. Delivery and Commercial Impact: Licensing opportunities: The cutting-edge technology and broad-reaching applications described in the patent provide a strong basis for licensing opportunities for contract manufacturers and research organizations. Potential for future collaborations and partnerships: The intersection of gene editing and non-coding RNA technology might provide a promising landscape for further partnerships between pharmaceutical companies, academic researchers, and technology suppliers. Existence and ongoing market demand: The cutting-edge technology detailed within this patent will likely drive future interest, investment, and further research and development in the research and development of applications centered on MGE and gene editing. Ongoing Research in Gene Editing and Non-Coding RNAs With the emergence of novel gene editing tools, scientists are steadily advancing our understanding of non-coding RNAs and their involvement in the etiology of human disease. As gene editing technology evolves, so does its range of applications: including its use for disease screening, personalized medicine, and gene therapy. Technical progress and innovations in specific gene editing tools will define the future capacity to manipulate and manipulate both coding and non-coding genomic regions. Non-coding RNAs have significant therapeutic potential, and researchers will continue to strive for precise and efficient methods for their manipulation and application in biomedicine. The innovative technology encapsulated in United States Patent 9808587 plays a vital role in the current active area of research into long non-coding RNAs and gene editing, where non-coding RNAs appear to be an emerging target for biopharmaceutical applications. Outlook on Ongoing Applications and Relevant Technologies: Long non-coding RNAs continue to be an evolving area in the realm of gene regulation. As scientists focus on translating research into practical applications, gene editing technologies stand at the forefront of this transformative process. As research advances and technologies evolve, scientists anticipate significant progress in comprehensively understanding the biological importance of non-coding RNAs, their engagement in disease, and the potential of editing these non-coding RNAs for treating a range of complex diseases.

Drugs Protected by US Patent 9,808,587

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Branded Pharm	PROAIR HFA	albuterol sulfate	AEROSOL, METERED;INHALATION	021457-001	Oct 29, 2004	AB2	RX	Yes	Yes			Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y
Teva Branded Pharm	QVAR 80	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-001	Sep 15, 2000		DISCN	Yes	No			Y

International Family Members for US Patent 9,808,587

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011254958
Brazil	112012029106
Canada	2799625
Canada	2887315
Canada	2936362
Canada	3019694
Canada	3111537